Dalal Street under pressure as crude tops $110; Sensex, Nifty extend slide

 

BIZ MASALA  |  BUSINESS • MARKETS • PEOPLE • INSIGHT

Oil shock, West Asia tensions and inflation fears weigh on sentiment as benchmarks post a third straight session of losses.

By Biz Masala Desk  |  October 22, 2026

Editorial illustration; market levels and crude-price references reflect reported figures for 22 October 2026.

Indian equities extended their decline for a third consecutive session on Thursday, with rising crude oil prices and escalating tensions in West Asia adding to concerns about inflation and corporate costs. The BSE Sensex fell 460.30 points, or 0.62%, to close at 73,249.39, while the NSE Nifty 50 lost 123.70 points, or 0.54%, to settle at 22,687.65. Brent crude traded around $112 a barrel as concerns over possible supply disruption intensified.

The market close

Benchmark percentage declines on 22 October 2026; chart prepared by Biz Masala from reported closing data.

Selling was broad rather than confined to a handful of heavyweight shares. Reports on the session said 13 of 16 major sectoral indices ended lower, while mid-cap and small-cap stocks also weakened. Reliance Industries and HDFC Bank were among the large-cap drags; Nestlé India also declined after food-safety notices drew investor attention. Some financial and industrial stocks advanced, limiting benchmark losses.

Why crude matters to India

India imports most of the crude oil it consumes, so a sustained rise in global prices can lift the import bill and put pressure on the current account. The effects can spread through transport, aviation, paints, tyres, chemicals, logistics and other businesses that use fuel or petroleum-derived inputs. Companies may face a squeeze if input costs rise faster than they can adjust selling prices.

Higher energy costs can also complicate the inflation outlook. If price pressures prove persistent, households may have less room for discretionary spending and businesses may become more cautious about expansion. These are risks rather than automatic outcomes: the impact depends on how long oil stays elevated, exchange-rate movements, domestic fuel-price policy and companies’ ability to absorb or pass on costs.

Rupee under pressure

The rupee also weakened on Thursday. A PTI-sourced market report said it closed provisionally at ₹94.82 per US dollar, down 44 paise from the previous close, after trading as low as ₹94.94 intraday. A weaker rupee can make dollar-priced imports, including crude, more expensive in local-currency terms, although currency movements and oil prices do not always move in lockstep.

What businesses and investors should watch

·       Brent crude: whether prices remain above $110 a barrel or retreat as supply-risk concerns change.

·       Inflation and policy signals: whether higher energy costs feed into broader prices and expectations.

·       Corporate margins: sensitivity among airlines, paints, tyres, chemicals, transport and other oil-linked sectors.

·       Currency and flows: rupee volatility, foreign portfolio flows and the impact of large primary-market activity.

·       Market breadth: whether selling remains widespread or stabilises in the next sessions.

The Biz Masala takeaway

Thursday’s fall reflects a familiar vulnerability in an oil-importing economy: a geopolitical shock can quickly become a market, currency and cost-of-business concern. One session does not establish a longer-term trend, but investors and companies have reason to watch the duration of the crude spike—not just the headline price. If oil remains elevated, pressure could shift from sentiment to earnings, input costs and household purchasing power.

Market information only; this story is not investment advice.

 

BIZ MASALA  |  BUSINESS • MARKETS • PEOPLE • INSIGHT

BIZ MASALA

Business. Markets. People. Insight.

Comments

Post a Comment

Popular posts from this blog

THE GREAT INDIAN CINEMA RESET

Image
  BIZ MASALA | BUSINESS. MARKETS. PEOPLE. INSIGHT. From Bollywood's dominance to the pan-India blockbuster: how regional cinema, streaming and changing audience behaviour rewrote the business of Indian films By Murthy ASR | Biz Masala | 17 October 2026 Hero artwork created for this story; conceptual illustration, not a documentary photograph. The opening scene: A business no longer controlled by one city For decades, Mumbai occupied the commanding heights of Indian cinema. Hindi films enjoyed cultural and commercial reach, while Telugu, Tamil, Malayalam and Kannada cinema had powerful home markets but more limited national distribution. S. S. Rajamouli's Baahubali: The Beginning (2015) helped demonstrate that a film rooted in one linguistic industry could travel nationally when storytelling, scale, marketing and distribution worked together. Baahubali 2 and later successes from Telugu and Kannada cinema reinforced the lesson. A decade later, dubbed releases are ...
Read more

SINGARENI COAL PUZZLE : THE CONTRACT QUESTION

Image
  What the CAG found in Singareni’s coal operations—and what remains to be answered By Murthy ASR   |   Biz Masala Investigative Series The audit trail is public. The follow-through is the next question. Singareni Collieries Company Limited (SCCL) is jointly owned by the Governments of Telangana (51%) and India (49%). It is not simply a mining company: its coal feeds power generation and industry, and its operating decisions have consequences for workers, consumers and public finances. A subject-specific compliance audit by the Comptroller and Auditor General of India (CAG), covering overburden removal, coal transportation and stowing-material contracts during 2018–19 to 2022–23, put several contract-design and operational questions on the public record. The report was tabled in the Telangana legislature on 30 March 2026. Its findings are historical and specific to the contracts and periods examined; they do not, by themselves, establish the cause of later pro...
Read more

WHO TESTS THE MEDICINES INDIA MAKES?

Image
  BIZ MASALA SIGNATURE STORY Inside the business of pharmaceutical testing laboratories — the money, the market and the science behind a medicine’s quality By Murthy ASR   |   18 October 2026 Illustrative editorial image: pharmaceutical analytical testing laboratory. A medicine may be manufactured on a modern production line, packed in a clean facility and shipped across the world. But before a batch can be trusted, its quality has to be demonstrated. Behind that assurance is a less visible industry: laboratories that test ingredients, finished formulations, impurities, stability and, where relevant, biological characteristics. For India, this is more than a technical service. The country’s pharmaceutical manufacturers supply domestic patients and regulated markets overseas. Their products must meet specifications, documentation requirements and regulatory expectations that vary by medicine and destination. Testing laboratories help generate the evidence on ...
Read more